PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer

NCT03740893 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

119

Enrollment

OTHER

Sponsor class

Conditions

Breast Neoplasm
Triple Negative Breast Cancer (TNBC)
HRD

Interventions

DRUG: AZD6738
DRUG: Olaparib
DRUG: Durvalumab

Sponsor

Institute of Cancer Research, United Kingdom

Collaborators

[object Object]